Dr. Reddy's rises on India distribution deal for Takeda's dengue vaccine
BUZZ-Dr. Reddy's rises on India distribution deal for Takeda's dengue vaccine ** Shares of India's Dr. Reddy's REDY.NS rise as much as 2.76% to 1,207.50 rupees
** REDY's signed an agreement with Japanese drugmaker Takeda Pharmaceutical 4502.T to promote and distribute the Qdenga dengue vaccine in India
** India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccine cleared for the country
** Dr Reddy's said Qdenga, a two-dose dengue vaccine administered three months apart without the need for pre-vaccination screening, is expected to be available in India in the first half of 2027
** Thirty-six analysts have a "Hold" rating on avg; median PT is 1,221 rupees - data compiled by LSEG
** YTD, REDY down 4.2%
(Reporting by Urvi Dugar in Bengaluru)
((UrviManoj.Dugar@thomsonreuters.com; +91 9558725583; ))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption